AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04613193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood presssure reduction
Description: Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
Study NCT03831334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral minoxidil
Description: Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
Study NCT01617005 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
Study NCT03494972 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tetracyclin ointment
Description: During 3rd molar surgery
Study NCT03494972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracyclin ointment
Description: During 3rd molar surgery
Study NCT03061656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1st HDCT
Study NCT03061656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 1st HDCT
Study NCT03061656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 1st HDCT
Study NCT03061656 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I-MIBG
Description: 2nd HDCT
Study NCT03061656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 2nd HDCT
Study NCT03061656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 2nd HDCT
Study NCT02546791 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Study NCT02261662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone
Study NCT02261662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Topical Steroids alone will be used; Betamethasone
Study NCT02226705 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple transnasal endoscopic surgeries
Description: Transnasal endoscopic surgery extended to the skull base
Study NCT02895724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Oxygen
Description: Hyperbaric oxygen therapy
Study NCT00236158 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AAIR/DDDR pacemaker
Description: Pacemaker with single lead or dual lead
Study NCT04395612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib combined with brivanib
Description: Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
Study NCT04395612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib combined with toripalimab
Description: Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
Study NCT03126019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets administered orally with water and without regard to food
Study NCT01483482 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conservative Treatment
Description: Simple Sling
Study NCT01483482 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment
Description: Superior Locking plate
Study NCT04516382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Active drug
Study NCT03058224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGN-ES001
Description: Only active product will be compared with placebo as described in Arms and Interventions.
Study NCT03058224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parol 500 mg Tablets (acetaminophen)
Description: Analgesic Rescue Medication
Study NCT03058224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parol 500 mg Tablets (acetaminophen)
Description: Analgesic Rescue Medication
Study NCT03717051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) sampling
Description: 1-week free NRT samples (patch or gum)
Study NCT03794128 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection for research (next-generation sequencing [NGS])
Description: Participants will have whole blood collected for next-generation sequencing (NGS).
Study NCT03794128 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection for research (HLA typing)
Description: Participants will have whole blood collected for HLA typing.
Study NCT03717051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication counseling
Description: Medication counseling
Study NCT03717051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication counseling
Description: Medication counseling
Study NCT03310658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip-Stitch Soft Tissue Closure System
Description: The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
Study NCT02893553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: study 1 will be single blind. study 2 will be blinded randomized-control trial.
Study NCT02893553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: study 1 will be single blind. study 2 will be blinded randomized-control trial.
Study NCT02893553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: study 1 will be single blind. study 2 will be blinded randomized-control trial.
Study NCT02893553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will only be used for study arm 2, the randomized blinded phase.
Study NCT02563262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: body angles measurements during weightlessness
Study NCT05467618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillofacial surgery
Description: An incision on the skin over the mandible versus incision on the gingivae inside the mouth
Study NCT05901350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
Study NCT04723953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/MRI
Description: PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: 5 mg daily
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 5 mg daily
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg daily
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 5 mg daily
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study NCT02236806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study NCT03272659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysview
Description: 250 mL enema containing 1.6 mmol of hexaminolevulinate
Study NCT01448421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keystone Heart Embolic Deflection Device
Description: The Keystone Heart Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
Study NCT04113902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
Study NCT04067206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECORDED MOTHER'S VOICE
Description: The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
Study NCT04067206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
Study NCT04067206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MiniMuff
Description: MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
Study NCT00265096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
Study NCT00265096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo; golimumab
Description: SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
Study NCT00265096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: golimumab
Description: 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
Study NCT02795260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette - Guerin
Description: The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
Study NCT02795260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo of Bacillus Calmette - Guerin
Description: The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
Study NCT02976597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% 20ml on each side Sonar guided TAB
Description: Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
Study NCT02976597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 10mg
Description: Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
Study NCT02976597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 15mg
Description: Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
Study NCT01908673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HRV biofeedback
Study NCT01908673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASTM
Study NCT03179943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
Study NCT03179943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
Study NCT03550586 — intervention group
Intervention type: OTHER
Intervention: Questionaires
Description: Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
Study NCT01061918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis MF
Description: 20 patients in the Tecnis MF group.
Study NCT01061918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: 20 patients in the ReSTOR group.
Study NCT01472913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin sealant
Description: Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
Study NCT01472913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline water
Description: Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
Study NCT03562260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bipolar release
Description: the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
Study NCT01017653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
Study NCT01017653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
Study NCT04021992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab
Description: All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
Study NCT02446093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aglatimagene besadenovec
Description: Three courses of CAN-2409 + prodrug (valacylovir or acyclovir) will be delivered and timed with different phases of therapy: 1) after induction chemotherapy 2) during CR or post-SBRT, and 3) at time of surgery. Up to 2 additional courses of CAN-2409 + prodrug, if feasible, for subjects with disease progression or metastases.
Study NCT02446093 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
Study NCT02446093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: CR will start not more than 2 months after completion of induction chemotherapy. The chemotherapy component of CR may be selected as per institutional standard of care (SOC) and protocols for administration, and may include capecitabine, 5-FU, or gemcitabine. Radiation should consist of a total dose of 45-54 Gy in 1.8-2.0 Gy fractions concurrent with chemotherapy over 3-5.5 weeks.
Study NCT02446093 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiation therapy
Description: SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
Study NCT02446093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: SBRT should start no more than 2 months after completion of induction chemotherapy. For SBRT, the radiation should consist of a total dose of 25-50 Gy in divided fractions over 1-2 weeks.
Study NCT02446093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection should be performed within 8 weeks after completing CR or SBRT.
Study NCT02446093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection should be performed within 8 weeks after completing CR or SBRT.
Study NCT03122262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: DTG 50mg Oral Tablet once daily
Study NCT03122262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide
Description: TAF/FTC 25/200mg Oral Tablet once daily
Study NCT03122262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Study NCT03122262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Study NCT02056600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
Study NCT04420546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for increasing physical activity
Study NCT04420546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to choose from a list of strategies for avoiding self-harm
Study NCT02934113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iOTA
Description: The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
Study NCT02934113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HWPP
Description: Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
Study NCT02218385 — intervention group
Intervention type: DEVICE
Intervention: ForeCYTE Breast Aspirator
Description: ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
Study NCT01426490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C
Description: Vitamin C, 100 mg/d
Study NCT01426490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Description: Vitamin B6, 50mg/d
Study NCT01426490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid 400 microgram/d
Study NCT01426490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6 plus folic acid
Description: Vitamin B6, 50 mg; folic acid, 400 microgram
Study NCT02223247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Study NCT03436160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR826647
Description: 100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
Study NCT03436160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR909388
Description: 100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.